JP2017502016A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502016A5 JP2017502016A5 JP2016540574A JP2016540574A JP2017502016A5 JP 2017502016 A5 JP2017502016 A5 JP 2017502016A5 JP 2016540574 A JP2016540574 A JP 2016540574A JP 2016540574 A JP2016540574 A JP 2016540574A JP 2017502016 A5 JP2017502016 A5 JP 2017502016A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- cas number
- delta
- cancer
- intellikine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919606P | 2013-12-20 | 2013-12-20 | |
| US61/919,606 | 2013-12-20 | ||
| PCT/US2014/071744 WO2015095838A2 (en) | 2013-12-20 | 2014-12-19 | Cancer treatments using combinations of mek type i and erk inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502016A JP2017502016A (ja) | 2017-01-19 |
| JP2017502016A5 true JP2017502016A5 (enExample) | 2018-02-01 |
Family
ID=53403902
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016540574A Pending JP2017502016A (ja) | 2013-12-20 | 2014-12-19 | １型ｍｅｋ阻害剤およびｅｒｋ阻害剤の組み合わせを使用するがんの処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20160310477A1 (enExample) |
| EP (1) | EP3082422A4 (enExample) |
| JP (1) | JP2017502016A (enExample) |
| AU (1) | AU2014368925A1 (enExample) |
| WO (1) | WO2015095838A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2711558C (en) | 2008-01-04 | 2016-12-13 | Intellikine, Inc. | Phosphatidyl inositol-3 kinase inhibiting compounds |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| AU2012205669B2 (en) | 2011-01-10 | 2015-08-20 | Infinity Pharmaceuticals Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| KR102229478B1 (ko) | 2012-11-01 | 2021-03-18 | 인피니티 파마슈티칼스, 인코포레이티드 | Pi3 키나아제 동형단백질 조절인자를 사용하는 암의 치료 |
| US20150320755A1 (en) | 2014-04-16 | 2015-11-12 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| JP6886165B2 (ja) * | 2016-02-15 | 2021-06-16 | 国立大学法人山形大学 | ガン抑制薬及び抗腫瘍剤、腫瘍再発防止剤、腫瘍発生予防剤 |
| MX391135B (es) | 2016-06-24 | 2025-03-21 | Infinity Pharmaceuticals Inc | Terapias de combinacion. |
| JP7405408B2 (ja) * | 2017-05-16 | 2023-12-26 | バイオメッド バレー ディスカバリーズ，インコーポレイティド | 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法 |
| CN112402413B (zh) * | 2020-11-26 | 2022-03-08 | 重庆三峡医药高等专科学校 | 野马追倍半萜内酯b在制备抗肝癌药物中的应用及一种抗肝癌药物 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1110957A1 (en) * | 1999-12-24 | 2001-06-27 | Applied Research Systems ARS Holding N.V. | Benzazole derivatives and their use as JNK modulators |
| US20060094674A1 (en) * | 2002-07-05 | 2006-05-04 | Neel Benjamin G | Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| DK3305776T3 (da) * | 2004-05-14 | 2019-12-09 | Vertex Pharma | Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser |
| US20060079494A1 (en) * | 2004-09-27 | 2006-04-13 | Santi Daniel V | Specific kinase inhibitors |
| WO2008067069A2 (en) * | 2006-10-19 | 2008-06-05 | Oregon Health & Science University | Mitogen activated protein kinase phosphatase 4 (mkp4) and methods of use thereof |
| AR068046A1 (es) * | 2007-06-05 | 2009-11-04 | Schering Corp | Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer |
| WO2010097372A1 (de) * | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Verbindungen als bradykinin-b1-antagonisten |
| AU2010299835A1 (en) * | 2009-09-28 | 2012-04-05 | Centre National De La Recherche Scientifique | Irreversible inhibitors useful for the treatment of kinase-related pathologies |
| ES2616238T3 (es) * | 2010-10-06 | 2017-06-12 | Glaxosmithkline Llc, Corporation Service Company | Derivados de bencimidazol como inhibidores de PI3 quinasa |
-
2014
- 2014-12-19 US US15/105,945 patent/US20160310477A1/en not_active Abandoned
- 2014-12-19 EP EP14871339.9A patent/EP3082422A4/en not_active Withdrawn
- 2014-12-19 JP JP2016540574A patent/JP2017502016A/ja active Pending
- 2014-12-19 AU AU2014368925A patent/AU2014368925A1/en not_active Abandoned
- 2014-12-19 WO PCT/US2014/071744 patent/WO2015095838A2/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502013A5 (enExample) | ||
| JP2017502017A5 (enExample) | ||
| JP2017500320A5 (enExample) | ||
| RU2016129287A (ru) | Лечение злокачественных опухолей с применением комбинаций ингибиторов erk и raf | |
| JP2017502014A5 (enExample) | ||
| Neyns et al. | Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma | |
| Beuselinck et al. | Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases | |
| Nonnenmacher et al. | RIST: A potent new combination therapy for glioblastoma | |
| O’Sullivan | Overcoming endocrine resistance in hormone-receptor positive advanced breast cancer-the emerging role of CDK4/6 inhibitors | |
| Lindauer et al. | Dasatinib | |
| Budde et al. | Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received≥ 2 prior lines of therapy: pivotal results from a phase I/II study | |
| CN116036278A (zh) | 用于治疗具有非典型braf突变的癌症的组合物和方法 | |
| Matheson et al. | Glucocorticoids and selumetinib are highly synergistic in RAS pathway-mutated childhood acute lymphoblastic leukemia through upregulation of BIM | |
| Wagner et al. | Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study | |
| EA201200560A1 (ru) | Специфическая терапия, использующая интегриновые лиганды для лечения рака | |
| MX2021001807A (es) | Combinacion de un inhibidor de histona desacetilasa y un inhibidor de proteina cinasa y uso farmaceutico de la misma. | |
| CA2939464A1 (en) | Use of anti-ccr5 antibodies in graft versus host disease | |
| NZ723271A (en) | Fused imidazole derivatives useful as ido inhibitors | |
| EP4520398A3 (en) | Treatment of prostate cancer | |
| US11298362B2 (en) | Combination therapy with Notch and CDK4/6 inhibitors for the treatment of cancer | |
| EA200900912A1 (ru) | Специфическая терапия и лекарственное средство на основе интегриновых лигандов для лечения рака | |
| MX2015017629A (es) | Combinaciones farmaceuticas. | |
| Islamagic et al. | The efficacy of generic imatinib as first-and second-line therapy: 3-year follow-up of patients with chronic myeloid leukemia | |
| Hicks et al. | Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo | |
| Narayanan et al. | Discovery and preclinical characterization of novel small molecule TRK and ROS1 tyrosine kinase inhibitors for the treatment of cancer and inflammation |